Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Mar 3, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.6K

Niraparib: First Global Approval.

Lesley J Scott1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|May 6, 2017
PubMed
Summary
This summary is machine-generated.

Niraparib, a PARP inhibitor, is approved for ovarian cancer maintenance therapy. The NOVA trial showed it significantly extends progression-free survival in recurrent ovarian cancer patients, regardless of BRCA mutation status.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.6K
Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.9K

Related Experiment Videos

Last Updated: Mar 3, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.6K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.6K
Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.9K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Niraparib is an oral poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor.
  • It is approved in the USA for maintenance treatment in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer responding to platinum-based chemotherapy.

Purpose of the Study:

  • To summarize the development milestones of niraparib.
  • To highlight its first global approval for specific ovarian cancer types.

Main Methods:

  • The multinational, phase 3 NOVA trial evaluated niraparib in patients with platinum-sensitive, recurrent ovarian cancer.
  • Progression-free survival was assessed irrespective of germline BRCA (gBRCA) mutation or homologous recombinant deficiency (HRD) status.

Main Results:

  • Niraparib significantly prolonged median progression-free survival in the NOVA trial.
  • Efficacy was demonstrated across patient subgroups, including those with and without gBRCA mutations and with varying HRD levels.

Conclusions:

  • Niraparib offers a valuable maintenance treatment option for patients with recurrent ovarian cancer.
  • Its development signifies a milestone in PARP inhibitor therapy for gynecologic malignancies and other solid tumors.